CompletedNCT04531982
Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia
This study evaluated the safety and effectiveness of Pimavanserin for people with schizophrenia.
Medication studyAges 18–55Multiple countries
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Pimavanserin for people with schizophrenia.
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- Buenos Aires, Argentina · Ciudad Autonoma Buenos Aires, Argentina and 59 more locationsSee all locations and recruitment
- Activities
- Medication described in the protocol · Placebo comparator
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateStarted: August 5, 2020
- Recruitment status
- Completed
- Enrollment listed in the registry
- 454
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Argentina, Bulgaria, Croatia, ...
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT04531982
- Official title
Show the full official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia
Recruitment & locations
CompletedBuenos Aires, Argentina · Ciudad Autonoma Buenos Aires, Argentina · Córdoba, Argentina
58 more locations
- La Plata, Argentina
- Mendoza, Argentina
- Kazanlak, Bulgaria
- Burgas, Bulgaria
- Kardzhali, Bulgaria
- Lovech, Bulgaria
- Pleven, Bulgaria
- Plovdiv, Bulgaria
- Sofia, Bulgaria
- Tsarev Brod, Bulgaria
- Varna, Bulgaria
- Veliko Tarnovo, Bulgaria
- Vratsa, Bulgaria
- Zagreb, Croatia
- Hradec Králové, Czechia
- Klecany, Czechia
- Pilsen, Czechia
- Prague, Czechia
- Kalocsa, Hungary
- Budapest, Hungary
- Pécs, Hungary
- Bari, Italy
- Milan, Italy
- Torino, Italy
- Kaunas, Lithuania
- Šilutė, Lithuania
- Bialystok, Poland
- Bydgoszcz, Poland
- Gdansk, Poland
- Katowice, Poland
- Lublin, Poland
- Pruszków, Poland
- Torun, Poland
- Tonnel’nyy, Russia
- Lipetsk, Russia
- Moscow, Russia
- Saint Petersburg, Russia
- Samara, Russia
- Smolensk, Russia
- Tomsk, Russia
- Yaroslavl, Russia
- Belgrade, Serbia
- Kovin, Serbia
- Kragujevac, Serbia
- Niš, Serbia
- Novi Kneževac, Serbia
- Barcelona, Spain
- Madrid, Spain
- Oviedo, Spain
- Valladolid, Spain
- Zamora, Spain
- Smila, Ukraine
- Kropyvnytskyi, Ukraine
- Kyiv, Ukraine
- Kharkiv, Ukraine
- Odesa, Ukraine
- Czechia
- Russia
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Pimavanserin for people with schizophrenia.
Who is behind this study?
The study sponsor is ACADIA Pharmaceuticals Inc.
Did this study involve medication?
Yes. The study involved medication, including Pimavanserin and Placebo.
Who was this study for?
Listed age limits: 18 years to 55 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedEUCTR 2011-004790-90
A 12-WEEK, MULTICENTER, OPEN-LABEL EXTENSION STUDY IN SUBJECTS WITH SCHIZOPHRENIA
Italy, Slovakia
CompletedEUCTR 2016-000061-23
A 12-Week, Open-Label Extension Study of Lurasidone (SM-13496) in Subjects with Schizophrenia
Poland, Slovakia
CompletedEUCTR 2008-002247-16
A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmit...
France, United Kingdom, Belgium, + 10 others